MeSH D015477 - myelomonocytic leukemia chronic
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Accord Healthcare | Azacitidine | Azacitidine | 2018-07-02 | |||
| Azacitidine | Azacitidine Accord | 2020-02-13 | ||||
| Allergan | Azacitidine | Azacitidine | 2016-04-29 | |||
| Amneal Pharmaceuticals | Azacitidine | Azacitidine | 2022-02-03 | |||
| betapharm Arzneimittel | Azacitidine | Azacitidine betapharm | 2020-03-24 | |||
| Bristol Myers Squibb | Azacitidine | Onureg | 2029-05-14 | 2020-09-01 | $168 M | Y2023 |
| Azacitidine | Vidaza | 2004-05-19 | $200 M | Q4/20-Q3/21 | ||
| Celgene | Azacitidine | Azacitidine Celgene | 2019-08-02 | |||
| Cipla | Azacitidine | Azacitidine | 2018-05-04 | |||
| Dr Reddys Laboratories | Azacitidine | Azacitidine | 2013-09-16 | |||
| Eugia Pharma Specialties | Azacitidine | Azacitidine | 2022-12-30 | |||
| Eurohealth International | Azacitidine | Azacitidine | 2020-06-08 |
1
2
>
Clinical Trials
Historical Success Rate
Phase 1
63%84/133
Phase 2
27%31/113
Phase 3
7%3/41
Approved: 2Overall Success rate: 1%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use